The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the “clinically non-functioning” pituitary adenomas in vitro

The findings indicate that selective sst1, sst2 and sst5 receptors agonists, SST/DA chimera and D2-dopamine receptor agonist bromocriptine affect the viability of some, but not all, “clinically non-functioning” pituitary adenomas in vitro. The most effective was bromocriptine. The investigated somatostatin analogs including SST/DA chimera exerted roughly similar inhibitory effects. Further studies are needed to fully evaluate the potential usefulness of these compounds in the pharmacological treatment of “non-functioning” pituitary tumors.